GlassScriptPhysician profile
Reagan Viney
NPI 1205034766
$2,777.07
in general payments reported to CMS, 2019-2025
33 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Obstetrics provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $723 · 2020: $382 · 2021: $512 · 2022: $559 · 2023: $249 · 2024: $228 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $601.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $672.64 | 2019-2024 | Ubrelvy, Synthroid |
| Bayer Healthcare Pharmaceuticals INC. | $338.55 | 2019-2023 | |
| Amgen INC. | $302.33 | 2019-2025 | Prolia, Evenity |
| Astellas Pharma US INC | $251.51 | 2019-2025 | Veozah |
| Exeltis, USA INC. | $159.36 | 2019-2020 | |
| Radius Health, INC. | $132.97 | 2019-2024 | Tymlos |
| Hologic Sales and Service, LLC | $111.98 | 2021-2025 | Myosure Tissue Removal Device, Novasure |
| Organon LLC | $110.46 | 2022-2024 | Nexplanon |
| Avion Pharmaceuticals | $71.23 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $69.63 | 2020-2023 | Trintellix |
| Axonics, INC. | $51.84 | 2021-2022 | |
| Daiichi Sankyo INC. | $46.20 | 2022 | |
| Coopersurgical, INC. | $45.91 | 2020 | |
| Allergan, INC. | $45.91 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $42.94 | 2025 | Myfembree |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $42.25 | 2021-2023 | Monoferric |
| Lupin INC. | $35.86 | 2019 | |
| Intuitive Surgical, INC. | $31.09 | 2019 | |
| Biogen, INC. | $21.89 | 2025 | Zurzuvae |
| Ortho-Clinical Diagnostics, INC. | $21.49 | 2021 | |
| Mayne Pharma Commercial LLC | $19.64 | 2023 | |
| Lilly USA, LLC | $17.11 | 2025 | Zepbound |
| Vivus LLC | $16.81 | 2020 | |
| Therapeuticsmd, INC. | $14.82 | 2022 | |
| Vertical Pharmaceuticals, LLC | $14.79 | 2019 | |
| Shield Therapeutics INC | $13.49 | 2023 | Accrufer |
| Pfizer INC. | $13.49 | 2024 | |
| Exact Sciences Corporation | $13.08 | 2024 | Cologuard Collection Kit |
| Genentech USA, INC. | $12.96 | 2020 | |
| Mission Pharmacal Company | $11.94 | 2020 | |
| Amag Pharmaceuticals, INC. | $11.86 | 2019 | |
| Assertio Therapeutics, INC. | $11.04 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reagan Viney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.